华润啤酒-R(80291)、安踏体育-R(82020)、李宁-R(82331)上一交易日沽空比率位于前三位，分别为 100.00%、100.00%、100.00%。泡泡玛特(09992)、小米集团-W(01810)、阿里巴巴-W(09988)的沽空金额 位居前三，分别为12.09 亿元、10.75 亿元、9.74 亿元。中国中车(01766)、李宁-R(82331)、中国平安- R(82318)的偏离值位居前三，分别为42.51%、38.82%、30.07%。 前十大沽空比率排行 | 股票名称 | 沽空金额 | 沽空比率↓ | 偏离值 | | --- | --- | --- | --- | | 华润啤酒-R(80291) | 19.28 万元 | 100.00% | 25.37% | | 安踏体育-R(82020) | 9.50 万元 | 100.00% | 12.50% | | 李宁-R(82331) | 10.09 万元 | 100.00% | 38.82% | | 联想集团-R(80992) | 456.22 万元 | 82.43% | 2.97% | | 中国平安-R(82318) | 397.47 ...

友邦保险-R(81299)、京东健康-R(86618)、百度集团-SWR(89888)上一交易日沽空比率位于前三位，分别 为100.00%、100.00%、95.46%。泡泡玛特(09992)、阿里巴巴-W(09988)、小米集团-W(01810)的沽空金 额位居前三，分别为13.00 亿元、12.60 亿元、10.64 亿元。百度集团-SWR(89888)、深圳高速公路股份 (00548)、商汤-WR(80020)的偏离值位居前三，分别为62.11%、37.02%、34.65%。 前十大沽空比率排行 前十大沽空偏离值排行 | 股票名称 | 沽空金额 | 沽空比率 | 偏离值↓ | | --- | --- | --- | --- | | 百度集团-SWR(89888) | 119.43 万元 | 95.46% | 62.11% | | 深圳高速公路股份(00548) | 164.67 万元 | 48.73% | 37.02% | | 商汤-WR(80020) | 15.48 万元 | 87.41% | 34.65% | | 中国平安-R(82318) | 245.20 万元 | 72.58% | 33.06% ...

Core Viewpoint - The article emphasizes China's dominant position in the global pharmaceutical supply chain, particularly in the production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which poses a significant asymmetric threat to U.S. national security [4][5]. Group 1: China's Dominance in Pharmaceutical Supply Chain - China holds a near-monopoly in the production of various pharmaceutical raw materials, with over 90% of global antibiotic intermediates supplied by China [18]. - Approximately 70%-80% of global vitamin production capacity is controlled by China, making it a critical player in the pharmaceutical industry [19]. - China's low-cost, high-output chemical manufacturing capabilities create significant barriers for competitors, allowing it to define prices and capacities in the market [21]. Group 2: Impact of Geopolitical Tensions - The U.S.-China trade tensions have led to concerns about the dependency of the U.S. on Chinese pharmaceutical supplies, which could lead to drug shortages in critical situations [9][10]. - The article illustrates a hypothetical scenario where geopolitical tensions could disrupt the supply of essential medications, highlighting the risks of "asymmetric interdependence" [7][9]. - The ongoing drug shortage issues in the U.S. are exacerbated by the complex global supply chain, where many active ingredients are sourced from China [10][11]. Group 3: Historical Context and Strategic Decisions - The article discusses the historical context of the pharmaceutical industry's shift, where Western companies outsourced low-margin API production to lower-cost countries, primarily China, while retaining high-margin R&D and marketing functions [23][24]. - This outsourcing has led to a significant loss of industrial capability in the West, as the foundational skills and infrastructure for API production have diminished [32]. Group 4: Challenges for India as an Alternative - India, often referred to as the "world's pharmacy," lacks the complete supply chain necessary for API production, relying heavily on Chinese intermediates [36][38]. - Despite efforts to establish a domestic API supply chain, India's progress is hindered by infrastructure challenges and the dominance of Chinese suppliers [37][39]. Group 5: Future Outlook and Strategic Recommendations - The article suggests that China is transitioning from merely being a low-cost producer to becoming a leader in technology and standards within the pharmaceutical industry [43]. - As geopolitical tensions rise, the need for China to innovate in green technologies and maintain its competitive edge in the pharmaceutical supply chain becomes critical [55][56]. - The future of the pharmaceutical industry will focus on balancing efficiency and safety, with the ability to provide cost-effective and safe drugs being a key determinant of success [58].

投资逻辑： 本周 Q4 公募基金医药持仓情况出炉，Q4 公募基金医药持仓占比为 8.11%，环比减少 1.66pp；剔除主动医药基金后， 公募基金医药持仓占比为3.90%，环比减少1.36pp。创新药ETF在Q4规模达到1006.2亿元，占医药基金比例为13.11%， 环比减少 1.35pp。创新药赛道在 25Q4 展现出了较强的韧性，其中单季医药基金/非药基金针对化学制剂持仓在医药 中占比+0.82%/-2.36%。受到地缘政治因素扰动，CXO 板块持仓比例有所下降。医疗设备赛道得益于脑机接口、手术机 器人等创新产品海外映射叠加政策支持，持仓占比有所提升。非药基金对中药有一定加仓，主要系部分中药公司股息 率较高，具备防守属性。基金对药店持仓总体相对平稳。从个股维度来看，恒瑞医药、信达生物等创新药企持股基金 数均有不同程度下降。药明康德四季度持股比例有一定下降，主要是由于地缘政治和股东减持因素影响。泰格医药持 股比例有一定提升，主要是由于国内市场转暖，订单和报价层面均逐步向好。 药品：1 月 20 日，GSK 宣布将以 22 亿美金收购 PART，强化布局 IgE 抗体等炎症和自免领域，预计 26Q1 将完成 ...

2026年1月16日，陈影从旧金山飞回上海，飞机上坐满了中国创新药企的创始人、高管、投资者，大部分人看上去心情不错，他们刚参加完全球规模最大的 医疗健康盛会——摩根大通医疗健康大会（下称"JPM"）。 这是陈影第一次参加JPM。2025年10月，她所在的赛默罗生物收到了几家跨国药企的邀请，希望能在JPM期间洽谈合作。赛默罗生物有一款原始创新（first- in-class）药物已进入临床二期试验，并获得美国食品药品监督管理局（FDA）的孤儿药认定，这引起了跨国药企的兴趣。 陈影此行与五六家跨国公司进行了一对一会谈，奔波在会场、各大洽谈室之间，每天睡觉不超过5小时。许多参会者都有类似体验，赫吉亚生物创始人崔坤 元开玩笑说，参会最直接的收获是"比较累"。大家期望在四天的日程里尽可能捕捉最前沿的行业信息、与意向合作方深入沟通。 多位受访者对经济观察报表示，相比前几年，2026年JPM带来的正向预期更明显。尤其是对中国创新药企，几乎每家跨国公司都不掩饰对中国资产的兴趣。 经济观察报 记者 张英 他观察到，尽管FDA官员在JPM期间提及了中美创新药竞争，但并未强调保护主义政策，更多提及的是美国医院、FDA如何优化临床试 ...

A股上市公司业绩预告加速披露。Wind数据显示，截至1月23日16时，A股共有710家上市公司对外披露 2025年全年业绩预告，284家预喜，预喜比例为40%。从报喜的上市公司所在行业角度看，有色金属、 半导体、生物医药、硬件设备、化工、汽车与零配件等行业表现亮眼。 ● 本报记者 董添 近70家企业净利同比增逾100% 南方精工预计2025年全年实现归属于上市公司股东的净利润为3亿元至3.7亿元，同比增长1130%至 1417%。报告期内，公司归属于上市公司股东的净利润增长，主要源于公司对持有的江苏泛亚微透科技 股份有限公司等投资项目进行了公允价值评估，产生的公允价值变动收益在本报告期对公司税前利润的 影响金额预计为3亿元至3.2亿元之间，该公允价值变动收益属于非经常性损益。 净利润数值方面，共有106家上市公司预计2025年归属于上市公司股东的净利润下限超过1亿元，49家预 计超过3亿元，33家预计超过5亿元，13家预计超过10亿元。紫金矿业、药明康德、洛阳钼业、立讯精 密、盐湖股份等公司预计2025年归属于上市公司股东的净利润数值居前。 药明康德预计2025年全年实现营业收入约为454.56亿元，同比增长 ...

证券日报网讯 1月23日，药明康德在互动平台回答投资者提问时表示，公司持续聚焦自身独特的 CRDMO业务模式，高效极致服务全球客户，造福全球病患。通过CRDMO业务模式，公司能够迅速产 生行业洞见，及时服务客户新分子需求，保证公司长期发展。 （编辑 王雪儿） ...

Short Selling Ratios - China Resources Beer (80291) and JD Group (89618) have the highest short selling ratios at 100.00% each, followed by Lenovo Group (80992) at 95.62% [1] - The top ten short selling ratios include Li Ning (82331) at 93.21% and Anta Sports (82020) at 88.46% [1] Short Selling Amounts - Alibaba (09988) leads in short selling amount with 1.173 billion, followed by Baidu (09888) at 1.111 billion and Pop Mart (09992) at 1.049 billion [1] - Other notable companies in the top ten include Meituan (03690) at 814 million and China Life (02628) at 806 million [1] Deviation Values - JD Group (89618) has the highest deviation value at 37.56%, followed by China Ping An (82318) at 33.98% and China Huaneng (03788) at 33.27% [1] - Other companies with significant deviation values include SenseTime (80020) at 32.05% and Li Ning (82331) at 31.52% [1]

Group 1 - The A-share market experienced fluctuations at relatively high levels in Q4 2025, with a slight decrease in overall equity positions of public funds compared to Q3 2025 [1][2] - The average equity positions for stock and mixed funds were 89.06% and 81.05%, respectively, showing a minor decline from the previous quarter [2] - Major holdings in public funds included leading light module companies, with Zhongji Xuchuang and Xinyi Sheng surpassing Ningde Times and Tencent Holdings to become the top two heavyweights [1][4] Group 2 - Several actively managed equity funds significantly increased their positions, with notable examples including Bosera Huixing and GF Chengxiang, which raised their equity positions by 12.31 and 10.3 percentage points, respectively [2] - Fund managers expressed optimism about the A-share market for 2026, citing potential dual benefits from domestic and international liquidity [3][9] - The focus on technology sectors continued, with managers identifying investment opportunities in storage chips, solid-state batteries, and humanoid robots [7][10] Group 3 - The top 50 heavyweights in public funds were primarily concentrated in information technology, consumer goods, and investment sectors, with 18 stocks in the information technology sector [4][6] - AI-related stocks gained prominence, with Zhongji Xuchuang, Xinyi Sheng, and Hanwujing entering the top seven heavyweights due to the AI boom [4][6] - The number of innovative drug companies in the top 50 heavyweights decreased from eight to five by the end of Q4 2025, indicating a shift in investment focus [5] Group 4 - Fund managers anticipate that the AI investment theme will continue to be a primary focus, with expectations for rapid growth in AI applications in the coming years [9][10] - The investment strategy is shifting towards AI applications, including smart driving, edge AI, and humanoid robots, as the industry matures [9][10] - The overall sentiment among fund managers is that the AI-driven technology market will remain a significant area of investment for the next several years [9][10]

业绩增幅榜前三为回盛生物、南方精工、上海谊众，预计归母净利润增幅上限分别达1444.54%、 1417.00%、903.54%。 作为"预增王"，回盛生物在业绩预告中表示，海内外市场营收双升叠加技术升级、产能利用率提升及原 料药涨价，共同推动盈利能力大幅改善，预计全年归母净利润达2.35亿元至2.71亿元。 本报记者 张晓玉 A股市场迎来上市公司业绩预告密集发布期。 据Wind数据统计，截至1月22日12时30分，已有640家A股公司披露2025年业绩预告或业绩快报，其中 248家公司预喜（含预增、略增、扭亏、续盈），占比38.75%。 从增长幅度看，130家公司预计归母净利润最高增幅超过100%，其中，29家公司增幅超300%，11家公 司增幅超500%。 从盈利规模来看，行业龙头仍展现出强劲韧性。101家公司预计2025年年报最高净利润超5亿元，其中， 64家超10亿元，35家超20亿元，11家超50亿元，7家超100亿元。紫金矿业以520亿元的预计净利润暂居 榜首，洛阳钼业、药明康德分别以208亿元、191.51亿元位居第二和第三。 中国企业联合会特约研究员胡麒牧对《证券日报》记者表示："当前市场对新质 ...